Moreover, the expression of SOX4 in lung ADCs harbouring the EGFR was also induced by inhibition of EGFR signalling, suggesting that combination of RTK inhibitors, including ALK inhibitors and EGFR inhibitors, along with a p53 activator could be widely applicable to treat many tumours harbouring aberration in RTKs including the EGFR in lung ADCs (Supplementary Figure 6e). Here, SOX4 is linked to medical procedure.